CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma

CANbridge Life Sciences

Status: Unknown

Conditions: Glioblastoma

Study type: Observational

Funder types: Industry

Identifiers

NCT03152708

CAN-B1-008-L-009

Details and patient eligibility

About

This study was conducted on the post-operative tumor tissues from 62 GBM patients. 20 slices are necessary for all the CD95 and CpG2 test in the central lab by the methods of immunisation and DNA methylation.

Enrollment: 62 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Chinese nationality
• No limits on Gender and age
• First diagnosed GBM
• Brain tumor tissue cytological diagnosis of glioblastoma (GBM, pleomorphic glioblastoma, WHO level IV)

Exclusion criteria

• Other types of glioma by histological diagnosis
• Tumor tissue not eligible for the central laboratory testing standard
• No enough tumor tissue for the central laboratory test